Clinical Trial

Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical Prostatectomy

Study acronym: PPSARP
Recruiting
View on ClinicalTrials.gov →
Summary
This prospective observational study aims to evaluate the prognostic significance of early postoperative prostate-specific antigen (PSA) levels in patients undergoing radical prostatectomy for prostate cancer. No investigational interventions will be performed. All diagnostic procedures, follow-up assessments, and treatments will be conducted in accordance with standard clinical practice and established prostate cancer management guidelines. Participation in the study will not influence treatment decisions.
Trial Details
NCT Number NCT07516886
Lead Sponsor Lithuanian University of Health Sciences
Conditions Prostate Cancer (Post Prostatectomy), Prostate Cancer (Adenocarcinoma), Prostate Cancer (Diagnosis), Prostate Specific Antigen, Radical Prostatectomy
Enrollment 500 participants
Start Date 2024-01-22
Primary Completion 2039-07 (estimated)
Study Completion 2039-07 (estimated)
Updated on ClinicalTrials.gov 2026-04-08